Molecular signature analysis: Using the myocardial transcriptome as a biomarker in cardiovascular disease

Michelle M. Kittleson, Joshua Hare

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

With the emergence of microarray technology, it is now possible to simultaneously assess the expression of tens of thousands of gene transcripts, providing a resolution and precision of phenotypic characterization not previously possible. In the field of cardiomyopathy, microarray studies have largely focused on gene discovery, identifying differentially expressed genes characteristic of diverse disease states, through which novel genetic pathways and potential therapeutic targets may be elucidated. However, gene expression profiling may also be used to identify a pattern of genes (a molecular signature) that serves as a biomarker for clinically relevant parameters. One study thus far does demonstrate that a molecular signature can accurately identify etiology in cardiovascular disease, supporting ongoing efforts to incorporate expression-profiling-based biomarkers in determining prognosis and response to therapy in heart failure. Microarray research in cardiomyopathy is still in its earliest stages. Nevertheless, the ultimate potential application of transcriptome-based molecular signature analysis is individualization of the management of patients with heart failure, whereby a patient with a newly diagnosed cardiomyopathy could, through molecular signature analysis, be offered an accurate assessment of prognosis and how individualized medical therapy could affect his or her outcome.

Original languageEnglish
Pages (from-to)130-138
Number of pages9
JournalTrends in Cardiovascular Medicine
Volume15
Issue number4
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Cardiomyopathies
Transcriptome
Cardiovascular Diseases
Biomarkers
Heart Failure
Genes
Genetic Association Studies
Gene Expression Profiling
Therapeutics
Technology
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Molecular signature analysis : Using the myocardial transcriptome as a biomarker in cardiovascular disease. / Kittleson, Michelle M.; Hare, Joshua.

In: Trends in Cardiovascular Medicine, Vol. 15, No. 4, 01.05.2005, p. 130-138.

Research output: Contribution to journalArticle

@article{42a3b1d064824cfeb4e62eeb9e9ec432,
title = "Molecular signature analysis: Using the myocardial transcriptome as a biomarker in cardiovascular disease",
abstract = "With the emergence of microarray technology, it is now possible to simultaneously assess the expression of tens of thousands of gene transcripts, providing a resolution and precision of phenotypic characterization not previously possible. In the field of cardiomyopathy, microarray studies have largely focused on gene discovery, identifying differentially expressed genes characteristic of diverse disease states, through which novel genetic pathways and potential therapeutic targets may be elucidated. However, gene expression profiling may also be used to identify a pattern of genes (a molecular signature) that serves as a biomarker for clinically relevant parameters. One study thus far does demonstrate that a molecular signature can accurately identify etiology in cardiovascular disease, supporting ongoing efforts to incorporate expression-profiling-based biomarkers in determining prognosis and response to therapy in heart failure. Microarray research in cardiomyopathy is still in its earliest stages. Nevertheless, the ultimate potential application of transcriptome-based molecular signature analysis is individualization of the management of patients with heart failure, whereby a patient with a newly diagnosed cardiomyopathy could, through molecular signature analysis, be offered an accurate assessment of prognosis and how individualized medical therapy could affect his or her outcome.",
author = "Kittleson, {Michelle M.} and Joshua Hare",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.tcm.2005.05.007",
language = "English",
volume = "15",
pages = "130--138",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Molecular signature analysis

T2 - Using the myocardial transcriptome as a biomarker in cardiovascular disease

AU - Kittleson, Michelle M.

AU - Hare, Joshua

PY - 2005/5/1

Y1 - 2005/5/1

N2 - With the emergence of microarray technology, it is now possible to simultaneously assess the expression of tens of thousands of gene transcripts, providing a resolution and precision of phenotypic characterization not previously possible. In the field of cardiomyopathy, microarray studies have largely focused on gene discovery, identifying differentially expressed genes characteristic of diverse disease states, through which novel genetic pathways and potential therapeutic targets may be elucidated. However, gene expression profiling may also be used to identify a pattern of genes (a molecular signature) that serves as a biomarker for clinically relevant parameters. One study thus far does demonstrate that a molecular signature can accurately identify etiology in cardiovascular disease, supporting ongoing efforts to incorporate expression-profiling-based biomarkers in determining prognosis and response to therapy in heart failure. Microarray research in cardiomyopathy is still in its earliest stages. Nevertheless, the ultimate potential application of transcriptome-based molecular signature analysis is individualization of the management of patients with heart failure, whereby a patient with a newly diagnosed cardiomyopathy could, through molecular signature analysis, be offered an accurate assessment of prognosis and how individualized medical therapy could affect his or her outcome.

AB - With the emergence of microarray technology, it is now possible to simultaneously assess the expression of tens of thousands of gene transcripts, providing a resolution and precision of phenotypic characterization not previously possible. In the field of cardiomyopathy, microarray studies have largely focused on gene discovery, identifying differentially expressed genes characteristic of diverse disease states, through which novel genetic pathways and potential therapeutic targets may be elucidated. However, gene expression profiling may also be used to identify a pattern of genes (a molecular signature) that serves as a biomarker for clinically relevant parameters. One study thus far does demonstrate that a molecular signature can accurately identify etiology in cardiovascular disease, supporting ongoing efforts to incorporate expression-profiling-based biomarkers in determining prognosis and response to therapy in heart failure. Microarray research in cardiomyopathy is still in its earliest stages. Nevertheless, the ultimate potential application of transcriptome-based molecular signature analysis is individualization of the management of patients with heart failure, whereby a patient with a newly diagnosed cardiomyopathy could, through molecular signature analysis, be offered an accurate assessment of prognosis and how individualized medical therapy could affect his or her outcome.

UR - http://www.scopus.com/inward/record.url?scp=23744508793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744508793&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2005.05.007

DO - 10.1016/j.tcm.2005.05.007

M3 - Article

C2 - 16099376

AN - SCOPUS:23744508793

VL - 15

SP - 130

EP - 138

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 4

ER -